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1552-5260/ 2015 Thmately lead to dementia. Genome-wide association studies have uncovered many genetic variants
conferring risk of neurodegenerative diseases, but their role in cognitive impairment remains unex-
plored.
Methods: In the prospective, population-based Rotterdam Study, 3605 nondemented persons aged
55 years were genotyped, screened for mild cognitive impairment (MCI) in 2002 to 2005 and un-
derwent continuous follow-up for dementia until 2012.Weighted polygenic risk scores of genetic var-
iants for Alzheimer’s disease (AD), Parkinson’s disease (PD), and the frontotemporal lobar
degeneration/amyotrophic lateral sclerosis disease spectrum (FTLD/ALS) were constructed and
investigated for association with MCI and the subsequent conversion to dementia.
Results: In total, 360 (10.0%) persons had MCI, of whom 147 (4.1%) were amnestic and 213 (5.9%)
nonamnestic. The AD risk score was associated with both MCI subtypes (odds ratio for all MCI 1.15
[95% CI, 1.03–1.28]), whereas PD and FTLD/ALS risk scores were associated only with nonamnes-
tic MCI (odds ratios 1.15 [1.00–1.32] and 1.19 [1.03–1.37], respectively). The AD risk score, but not
PD and FTLD/ALS risk scores, was associated with an increased risk of dementia (hazard ratio 1.55
[1.37–1.77]).
Discussion: Genetic evidence supports the view that multiple neurodegenerative pathways lead to
MCI and that the subsequent conversion to dementia, primarily of the AD subtype, is mainly due
to the AD pathway(s).
 2015 The Alzheimer’s Association. Published by Elsevier Inc. All rights reserved.Keywords: Mild cognitive impairment; Genetics; Dementia; Alzheimer’s disease; Parkinson’s disease; Frontotemporal lobardegeneration; Amyotrophic lateral sclerosis1. Introduction
Aging populations worldwide face an increasing burden
of neurodegenerative diseases [1]. Major diseases, in terms
of mortality, morbidity, and health care costs, includet: None.
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e Alzheimer’s Association. Published by Elsevier Inc. All rAlzheimer’s disease (AD), Parkinson’s disease (PD), fronto-
temporal lobar degeneration (FTLD), and amyotrophic
lateral sclerosis (ALS). Cognitive impairment is the most
prominent in AD [2,3] and FTLD [4], but it is also an impor-
tant feature of PD [5] and ALS [6]. Our genetic understand-
ing of these neurodegenerative diseases has improved
considerably over the past years through large-scale
genome-wide association studies that have identified a large
number of novel risk variants [7–12]. However, due to theights reserved.
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it remains largely unknown how these genetic variants lead
to cognitive decline and ultimately clinical disease.
The severe deterioration in cognitive function seen in
neurodegenerative diseases is often preceded by a preclini-
cal stage with only subtle cognitive deficits that deteriorate
over time. Mild cognitive impairment (MCI) describes this
intermediate state and is variable in both its clinical presen-
tation and conversion to dementia [3]. Given that MCI pro-
vides a window of opportunity for preventive or therapeutic
interventions, it is important to uncover risk factors for MCI
and factors that lead to the conversion of MCI to dementia.
The diagnosis of MCI is made on clinical grounds and,
although cognitive abilities are highly heritable [13], the ge-
netic basis of MCI remains largely unknown [2]. Apolipo-
protein E (APOE), the major risk gene in AD, is known to
play a role inMCI [14], but whether other, recently identified
genetic variants for neurodegenerative diseases are also
involved has yet to be determined.
In this study, we investigated the effect of genetic risk var-
iants of AD, PD, FTLD, and ALS onMCI status and the sub-
sequent conversion of MCI to dementia.2. Methods
2.1. Setting
The Rotterdam Study is an ongoing population-based
cohort study in the Netherlands investigating diseases in
the elderly and currently consists of 14,926 residents of Rot-
terdamwhowere aged 45 years or more at baseline [15]. The
initial cohort was started in 1990 and expanded in 2000 and
2005. The whole population is subject to a set of multidisci-
plinary examinations every 4 years. Genotyping was per-
formed in 11,496 participants at study entry. MCI status
was assessed only between 2002 and 2005, and was available
in 4198 participants. This resulted in a final study population
of 3605 nondemented persons with information available on
both genome-wide genotyping and MCI status, who were
subsequently followed up for the development of dementia
until 2012. The Rotterdam Study has been approved by the
medical ethics committee according to the Population Study
Act Rotterdam Study, executed by the Ministry of Health,
Welfare and Sports of the Netherlands. A written informed
consent was obtained from all participants.
2.2. Genotyping
The Illumina 550K and 550K duo arrays were used for
genotyping. We removed samples with call rate lower than
97.5%, gender mismatch, excess autosomal heterozygosity,
duplicates or family relations and ethnic outliers, and vari-
ants with call rate lower than 95.0%, failing missingness
test, Hardy-Weinberg equilibrium P-value ,1026, and mi-
nor allele frequency ,1%. Genotypes were imputed using
Markov Chain Haplotyping (MaCH)/minimac software to
the 1000 Genomes phase I version 3 reference panel (allpopulation). APOE ε4 genotyping was performed separately
using polymerase chain reaction and was available in 3524
(97.8%) participants [16].2.3. Genetic risk scores
We searched the literature for genetic variants for AD,
PD, FTLD, and ALS. Given our population-based setting,
we focused on sporadic mutations and therefore excluded
mutations of familial disease (e.g., presenilin 1 [PSEN1],
presenilin 2 [PSEN2], amyloid precursor protein [APP] in
AD and granulin [GRN] in FTLD). Because various candi-
date gene studies have been performed that implicated hun-
dreds of variants in these four neurodegenerative diseases,
we have tried to minimize false-positives by including
only those variants that were genome-wide significant in
the largest meta-analysis of that disease. We chose to use
this objective threshold and did not base decisions on func-
tional work that potentially corroborated the findings.
Notable loci that did not pass this strict threshold were
CD33 and angiotensin-converting enzyme (ACE). Other
variants that were considered but not included were not gen-
otyped nor imputed with sufficient quality (R2, 0.5) in our
data set, and a suitable proxy variant was absent: these
were typically rare (triggering receptor expressed on
myeloid cells 2 [TREM2], phospholipase D family, member
3 [PLD3], b-Glucocerebrosidase [GBA]) or in the
poorly covered), human leukocyte antigen (HLA) region
(AD: rs111418223, PD: rs115736749, rs9275326).
For our analyses we identified 19 variants for AD, 25 var-
iants for PD, one variant for FTLD, and two variants for ALS
(Table 1) [7–12,17–19]. Because FTLD and ALS are
considered extremes of the same disease spectrum, and the
FTLD variant is also implicated in ALS, we decided to
pool the three variants together for increased power. The
variant rs3849943 is tagging the C9orf72 hexanucleotide
expansion, which itself was not assessed in our study [9].
Genetic risk scores were constructed by multiplying the
number of risk alleles by their reported odds ratio (after nat-
ural logarithm transformation) for the disease, and summing
this weighted allele score of each variant up into a disease
risk score for AD, PD, and FTLD/ALS. Similarly, a com-
bined genetic risk score of all neurodegenerative disease var-
iants was created.2.4. MCI screening
From 2002 to 2005 onward, we implemented extensive
cognitive testing to allow for the screening of MCI. All par-
ticipants of the three Rotterdam Study subcohorts who were
alive in 2002 to 2005 were invited to undergo these tests and
assessed for MCI. However, as the third subcohort of the
Rotterdam Study is comprised of relatively young partici-
pants (45 years and more), but still would yield a consider-
able number of screen-positives for MCI, it was not
included in this study population at risk.
Table 1
List of known genetic variants that increase risk of neurodegenerative diseases
Disease RS ID Chr. Position Locus Allele 1 Allele 2 OR
AD rs6656401 1 207692049 CR1 A G 1.18
AD rs6733839 2 127892810 BIN1 T C 1.22
AD rs35349669 2 234068476 INPP5D T C 1.08
AD rs190982 5 88223420 MEF2C G A 0.93
AD rs10948363 6 47487762 CD2AP G A 1.10
AD rs2718058 7 37841534 NME8 G A 0.93
AD rs1476679 7 100004446 ZCWPW1 C T 0.91
AD rs11771145 7 143110762 EPHA1 A G 0.90
AD rs28834970 8 27195121 PTK2B C T 1.10
AD rs9331896 8 27467686 CLU C T 0.86
AD rs10838725 11 47557871 CELF1 C T 1.08
AD rs983392 11 59923508 MS4A6A G A 0.90
AD rs10792832 11 85867875 PICALM A G 0.87
AD rs11218343 11 121435587 SORL1 C T 0.77
AD rs17125944 14 53400629 FERMT2 C T 1.14
AD rs10498633 14 92926952 SLC24A4 T G 0.91
AD rs4147929 19 1063443 ABCA7 A G 1.15
AD rs429358/rs7412 19 45411941/45412079 APOE ε4 ε2/3 3.69
AD rs7274581 20 55018260 CASS4 C T 0.88
PD rs114138760 1 154898185 GBA C G 1.57
PD rs35749011 1 155135036 GBA A G 1.76
PD rs823118 1 205723572 RAB7L1 T C 1.13
PD rs10797576 1 232664611 SIPA1L2 T C 1.14
PD rs6430538 2 135539967 ACMSD T C 0.87
PD rs1474055 2 169110394 STK39 T C 1.21
PD rs12637471 3 182762437 MCCC1 A G 0.84
PD rs34884217 4 944210 TMEM175 A C 1.25
PD rs34311866 4 951947 TMEM175 T C 0.78
PD rs11724635 4 15737101 BST1 A C 1.12
PD rs6812193 4 77198986 FAM47 E T C 0.90
PD rs356182 4 90626111 SNCA A G 0.74
PD rs7681154 4 90763703 SNCA A C 0.84
PD rs199347 7 23293746 GPNMB A G 1.12
PD rs591323 8 16697091 FGF20 A G 0.92
PD rs117896735 10 121536327 INPP5F A G 1.77
PD rs329648 11 133765367 MIR4697 T C 1.10
PD rs76904798 12 40614434 LRRK2 T C 1.17
PD rs11060180 12 123303586 CCDC62 A G 1.10
PD rs11158026 14 55348869 GCH1 T C 0.89
PD rs2414739 15 61994134 VPS13 C A G 1.11
PD rs14235 16 31121793 STX1B A G 1.09
PD rs11868035 17 17715101 SREBF A G 0.94
PD rs12456492 18 40673380 RIT2 A G 0.91
PD rs8118008 20 3168166 DDRGK1 A G 1.11
FTLD rs1990622 7 12283787 TMEM106 B G A 0.61
ALS rs3849943 9 27543382 C9ORF72 C T 1.17
ALS rs34517613 17 26610252 SARM1 T C 0.83
Abbreviations: AD, Alzheimer’s disease; PD, Parkinson’s disease; ALS, amyotrophic lateral sclerosis; FTLD, frontotemporal lobar degeneration; Chr., chro-
mosome; MCI, mild cognitive impairment; OR, odds ratio; RA, risk allele.
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objectively measured cognitive impairment, in the absence
of dementia [3].
Subjective cognitive impairment was considered present
if persons reported complaints on any of three questions
on memory (difficulty remembering, forgetting what one
had planned to do, and difficulty finding words) or three
questions on everyday functioning (difficulty managing fi-
nances, problems using a telephone, and difficulty getting
dressed). Objective measures of cognitive functioning wereneuropsychological tests (Letter-Digit Substitution Task,
Stroop test, Verbal Fluency Test, and the 15-Word verbal
Learning Test based onRey’s recall of words) that were incor-
porated into robust compound scores of memory function,
information-processing speed, and executive function, as
described previously [20]. Scores lower than 1.5 SD of the
age- and education-adjusted means were considered indica-
tive of objective cognitive impairment. MCI was further clas-
sified as “amnestic” in case of an objective memory deficit
(irrespective of other domains), or as “nonamnestic” if only
Table 2
Study population characteristics
Characteristic Total (N 5 3605)
Demographics
Age, yrs 71.9 (7.2)
Females 2057 (58.2%)
Educational level
Primary education 360 (10.1%)
Lower vocational education 1022 (28.7%)
Lower secondary education 585 (16.4%)
Intermediate vocational education 967 (27.1%)
General secondary education 145 (4.1%)
Higher vocational education 438 (12.3%)
University 49 (1.4%)
Vascular risk factors
Hypertension 2912 (81.0%)
Diabetes mellitus 529 (14.7%)
Waist circumference, cm 93.6 (11.8)
Total cholesterol, mmol/L 5.61 (0.99)
HDL-cholesterol, mmol/L 1.45 (0.40)
Smoking
Never 1054 (29.2%)
Former 1998 (55.4%)
Current 553 (15.3%)
Cognition
Letter-digit substitution task, no. of items/min 27.1 (6.8)
Stroop test (color word interference), s 56.4 (21.0)
Verbal fluency test, no. of animals/min 20.9 (5.1)
15-word verbal learning test, no. of words 6.54 (2.69)
Diagnosis
MCI 360 (10.0%)
Amnestic 147 (4.1%)
Nonamnestic 213 (5.9%)
Dementia
Incident cases 191 (5.3%)
Follow-up time, yrs 6.04 (1.50)
Abbreviations: HDL, high-density lipoprotein; MCI, mild cognitive
impairment.
NOTE. Values are mean (SD) or number (percentage). Missing values are
present in educational level (n 5 39), hypertension (n 5 9), waist circum-
ference (n 5 9), and cholesterol levels (n 5 59).
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in the Rotterdam Study was previously described in more
detail [21].
2.5. Assessment of dementia
Participants were screened for dementia at each of the
Rotterdam Study examination rounds and additionally by
using information obtained from the general practitioners
and regional outpatient care centers (follow-up completed
until January 2012) [15]. Mini-Mental State Examination
(MMSE) [22] and the Geriatric Mental Schedule (GMS)
[23] were used to identify high-risk individuals (MMSE
,26 or GMS.0) for an additional interview with the Cam-
bridge Examination forMental Disorders in the Elderly [24].
When required, further neuropsychological testing and neu-
roimaging were used by a consensus panel for diagnosis ac-
cording to the established criteria for dementia (Diagnostic
and Statistical Manual of Mental Disorders, Third Edition,
Revised) and Alzheimer’s Disease (National Institute of
Neurological and Communicative Diseases and Stroke/Alz-
heimer’s Disease and Related Disorders Association)
[25,26].
2.6. Statistical analyses
Genetic risk scores were transformed into z-scores to
facilitate comparisons of their effect per standard deviation
increase across each score. Logistic regression models
were used to examine associations between the risk scores
and MCI status. To evaluate the conversion of MCI to de-
mentia and incident dementia in cognitively normal persons
separately, Cox proportional hazard models stratified for
MCI status were used. Additionally, the effects of individual
variants were explored and considered significant after Bon-
ferroni correction for the number of tested variants (P5.05/
47 5 .0011). Regression models were adjusted for age and
sex, and additionally for vascular risk factors. Furthermore,
potential interaction between the genetic risk scores and age-
at-onset of MCI and dementia was examined.
To determine diagnostic and predictive accuracy of the
genetic risk scores, the area under the receiver operating
curve was calculated for a basic model including age and
sex, and compared with a model additionally incorporating
the genetic risk scores. All analyses were performed with
SPSS version 22, IBM.3. Results
3.1. Population characteristics
Mean (standard deviation [SD]) age was 71.9 (7.2) years
and 2057 (57.1%) were women. A total of 360 (10.0%) par-
ticipants met the criteria for MCI, of whom 147 (4.1%) were
with amnestic and 213 (5.9%) with nonamnestic MCI. Mean
(SD) follow-up was 6.0 (1.5) years, during which 191 per-
sons were diagnosed with dementia, of whom 156 werewith AD. A detailed description of the population character-
istics can be found in Table 2.
3.2. MCI status
The association withMCI status was significant for the ge-
netic risk score of AD (odds ratio or OR5 1.15 [1.03–1.28])
and suggestive for PD (1.10 [0.99–1.23]) and FTLD/ALS
(1.09 [0.98–1.22]). Investigating subtypes of MCI separately,
we found an association with amnestic MCI for the risk score
of AD only (1.16 [0.99–1.36]) which attenuated after
excluding APOE from the risk score (1.11 [0.94–1.31]). In
contrast, risk scores ofAD, PD, and FTLD/ALSwere all asso-
ciated with the subtype of nonamnestic MCI (see Table 3).
The combined risk score for all neurodegenerative diseases
together was significantly associated with MCI, particularly
nonamnestic MCI. The associations were similar after an
additional adjustment for education and vascular risk factors
(see Supplementary Table 1).
Table 3
Associations of genetic risk scores for neurodegenerative diseases with mild cognitive impairment
Genetic risk score, per SD OR for MCI P-value OR for amnestic MCI P-value OR for nonamnestic MCI P-value
Alzheimer disease 1.15 (1.03–1.28) .011 1.16 (0.99–1.36) .062 1.14 (0.99–1.31) .063
Alzheimer disease without APOE 1.19 (1.07–1.33) .002 1.11 (0.94–1.31) .223 1.25 (1.09–1.44) .002
Parkinson disease 1.10 (0.99–1.23) .081 1.02 (0.86–1.20) .830 1.16 (1.01–1.33) .037
FTLD/ALS 1.09 (0.98–1.22) .130 0.97 (0.82–1.14) .680 1.19 (1.03–1.37) .019
Combined risk score 1.20 (1.08–1.34) .001 1.13 (0.96–1.33) .142 1.26 (1.09–1.44) .001
Abbreviations: SD, standard deviation; OR, odds ratio; MCI, mild cognitive impairment; APOE, apolopoprotein E; FTLD/ALS, frontotemporal lobar degen-
eration/amyotrophic lateral sclerosis.
NOTE. Values are odds ratios with 95% confidence intervals per SD of genetic risk score, adjusted for age and sex.
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make up the MCI diagnosis separately revealed that the AD
score associated strongly with subjective memory com-
plaints (Table 4). The AD score without APOE and PD
and FTLD/ALS primarily affected objective measures of
cognitive complaints, particularly information-processing
speed and executive function, although the PD score also
associated with problems getting dressed. No significant in-
teractions were detected between the risk scores and age-at-
onset of MCI. In single variant analyses, AD risk variant
rs6733839 near BIN1was associated with MCI after Bonfer-
roni correction (see Supplementary Table 2 for all single
variant results).3.3. Conversion to dementia
The risk score for AD, but not for PD and FTLD/ALS,
was associated with incident dementia. This association
was particularly pronounced for the conversion from MCI
(1.59 [1.23–2.05]). Exclusion of APOE attenuated the asso-
ciation of the AD risk score with incident dementia, which
remained only borderline significant among persons without
MCI (1.21 [1.02–1.43]). The combined genetic risk score
was highly significantly associated with incident dementia.
The associations were similar after additional adjustment
for vascular risk factors (see Supplementary Table 3). There
was a significant interaction between the AD genetic risk
score and age-at-onset of dementia (P 5.003), which indi-
cated a stronger genetic effect when age at onset was lower.
Among all variants individually, only APOE survived
multiple testing. Other AD variants that were related to inci-
dent dementia were rs983392 (MS4A6A), rs10948363
(CD2AP), and rs9331896 (CLU). Interestingly, rs6733839
(BIN1) which was associated with MCI, was not associated
with incident dementia. The results of the genetic risk scores
are summarized in Table 5 and of single variants in
Supplementary Table 4. Additionally, the AD risk score
without APOE was examined after the stratification for
APOE ε4 carrier status (see Supplementary Table 5).3.4. Diagnosis and predictive accuracy
The addition of the genetic risk scores to models of age
and sex for diagnosing MCI and predicting dementiaresulted in small increases of ,0.025 of the area under the
receiver operating curve (see Table 6).4. Discussion
We found in a population-based cohort study that a ge-
netic risk score for AD was associated with amnestic and
nonamnestic MCI, whereas genetic risk scores for PD and
FTLD/ALS only associated with nonamnestic MCI. Further-
more, only the genetic risk score for AD was associated with
incident dementia, which attenuated after the exclusion of
APOE. The diagnostic and predictive accuracy of these
risk scores was only modest.
We found that the genetic susceptibility to various neuro-
degenerative diseases associates with MCI. The clinical
concept of MCI could therefore reflect an underlying hetero-
geneity of disease pathways leading to the deterioration of
cognitive functions. Amnestic MCI, the subtype which in-
creases the risk of AD, was associated with APOE, but the
novel AD risk variants identified through genome-wide as-
sociation studies were related more to the nonamnestic sub-
type. AD genes might thus influence different cognitive
domains, with the common feature of (jointly) increasing
the risk of AD. The role APOE of in AD is well-
documented, and is often used as a model for “typical”
AD: neurodegeneration starting in the medial temporal
lobe, giving episodic memory problems, amnestic MCI,
and then leading to dementia. It is therefore interesting to
see that the novel genetic loci are acting differently from
APOE, and the underlying pathophysiological mecha-
nism(s) might also be different and thus result in this atypical
presentation. Studying the novel loci separately and in com-
bination could complement our current knowledge of the
pathophysiology, and might eventually even warrant more
detailed subtyping of the heterogeneous entity of AD. Non-
amnestic MCI was associated with various genetic risk fac-
tors of PD and FTLD/ALS, which indicates that the further
characterization of MCI subgroups might also be
appropriate.
Alternatively, these associations could be explained by
persons with incipient disease who were classified as having
MCI. However, all persons meeting the criteria for dementia,
including causes of AD, PD, and FTLD, were excluded from
the analyses withMCI, and a minimal contribution of ALS is
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H.H.H. Adams et al. / Alzheimer’s & Dementia 11 (2015) 1277-12851282expected because of our community-based setting. Unfortu-
nately, family members or caregivers were generally not pre-
sent during the center visits, and could therefore not be asked
about subjective cognitive complaints of the participant.
Also, visuospatial functions were not explicitly assessed.
However, given the extensive collection of both interview
data and cognitive tests for each participant, it seems un-
likely that this would results in a substantial number of un-
diagnosed MCI cases. Another consideration is that we
were unable to assess incident MCI, because MCI screening
was only performed at the baseline of our study. However,
because genetic variants reflect life-long exposure, reverse
causality or unmeasured confounding is highly unlikely.
A potential limitation is that we have not completed
follow-up of participants until the end of their lifetimes,
which would correspond to an expected 30 years of addi-
tional follow-up. Although mean age was already 72 years
at baseline, and Cox proportional hazard models took the
variation in starting age and follow-up time into account,
we further evaluated whether age-at-onset modifies the as-
sociation of the risk scores, which was true only for the
AD risk score including APOE. Nonetheless, competing
risks are a potential source of bias, and this bias remains
even after following persons until the end of their
lifetimes.
MCI is often called an intermediate stage, implicitly sug-
gesting that it is merely an earlier form of dementia with
more cognitive functions still remaining intact, but this
might not be an adequate representation of MCI. Although
risk factors between neurodegenerative diseases and MCI
overlap, many peoplewithMCI remain stable or can even re-
turn to normal [2,3]. In our study, the AD genetic risk score
was indeed associated with bothMCI and incident dementia,
but examining the individual risk variants separately
suggests that each of these two processes could be driven
by different factors; e.g., BIN1 contributes more to
initiating MCI (OR 5 1.32, P ,.001) than to conversion to
AD (OR 5 1.13, P 5.31). If validated in other studies,
these findings could help prioritize certain AD targets for
early intervention. Because only part of the MCI
population develops dementia, the heterogeneity of this
group could therefore provide an explanation why some
genes only predispose to MCI, namely that this factor for
example mostly causes a stable MCI subtype. Also, the
dementia trajectory spans decades, and even infant
changes have recently been implicated [27]. Rather than a
single process that is responsible for all dementia pathology
across its various stages, different processes might either
predispose to, initiate, or propagate cognitive decline.
Which process is affected by a gene, and in particular
when in the dementia trajectory this process is relevant,
might thus be reflected in stronger associations with MCI,
that are less prominent later (conversion to dementia),
such as with BIN1.
We note that most of our dementia cases were due to AD.
Therefore, we were unable to detect any association of the
Table 5
Associations of genetic risk scores for neurodegenerative diseases with incident dementia in the total population and stratified by mild cognitive impairment
status
Genetic risk score, per SD
Hazard ratio for conversion to dementia, per SD increase of the genetic risk score (95% confidence interval)
Total population
(n/N 5 191/3605) P
Persons with MCI
(n/N 5 55/360) P
Cognitively
normal persons
(n/N 5 136/3245) P
AD 1.56 (1.37–1.78) ,.001 1.59 (1.23–2.05) ,.001 1.53 (1.31–1.78) ,.001
AD without APOE 1.15 (1.00–1.32) .058 1.03 (0.79–1.34) .811 1.21 (1.02–1.43) .027
PD 0.90 (0.79–1.04) .159 0.95 (0.74–1.21) .669 0.89 (0.75–1.05) .162
FTLD/ALS 0.92 (0.80–1.06) .265 0.86 (0.66–1.12) .264 0.96 (0.81–1.14) .634
Combined risk score 1.34 (1.16–1.55) ,.001 1.35 (1.01–1.79) .040 1.33 (1.12–1.57) .001
Abbreviations: n, number of persons converting to dementia; N, cohort at risk; SD, standard deviation; AD, Alzheimer’s disease; PD, Parkinson’s disease;
MCI, mild cognitive impairment; APOE ε4, apolipoprotein E; FTLD/ALS, frontotemporal lobar degeneration/amyotrophic lateral sclerosis.
NOTE. All analyses are adjusted for age, sex, and MCI-status if applicable.
H.H.H. Adams et al. / Alzheimer’s & Dementia 11 (2015) 1277-1285 1283other genetic risk scores with dementia due to PD or FTLD/
ALS. It is possible that separate genetic risk scores increase
the risk of disease-specific dementia subtypes only, but this
needs to be studied further. An important consideration is
that variant rs3849943 is tagging the GGGGCC expansion
within open reading frame 72 (C9orf72), which was shown
to be responsible for this GWAS signal on chromosome 9
[9]. This expansion is present in 4% to 21% of sporadic
ALS cases [28,29]. Phenotypes of neurodegenerative
diseases are uncommon when less than 20 expansions are
present, and it usually requires more than 50 expansions
for ALS cases to develop dementia. Because we were
unable to assess the exact number expansions, and given
our population-based setting, it is possible that the average
number of expansions was low in this study. Future efforts
should therefore investigate this locus in more detail to un-
derstand its role in MCI and the subsequent conversion to
dementia.
Our diagnostic and prediction models incorporating the
genetic risk scores resulted in marginal improvement of
diagnosing MCI and predicting dementia. This is in line
with two previous studies that used a smaller set of variants
[30,31]. It has been questioned if a sufficient level ofTable 6
Areas under the curve for diagnosing mild cognitive impairment and predicting de
diseases
Area under the curve for MCI status (95% confidence
All
(n/N 5 360/3605)
Amnestic
(n/N 5 147/3392)
Nonamnes
(n/N 5 21
Basic model: age and sex 0.578 (0.547–0.609) 0.577 (0.528–0.626) 0.603 (0.56
1AD 0.588 (0.556–0.620) 0.592 (0.545–0.640) 0.614 (0.57
1AD without APOE 0.593 (0.562–0.625) 0.589 (0.541–0.636) 0.625 (0.58
1PD 0.582 (0.551–0.613) 0.577 (0.529–0.625) 0.612 (0.57
1FTLD/ALS 0.579 (0.547–0.611) 0.584 (0.536–0.631) 0.612 (0.57
1Combined risk score 0.594 (0.562–0.626) 0.590 (0.543–0.637) 0.627 (0.58
Abbreviations: MCI, mild cognitive impairment; AD, Alzheimer’s disease; APO
degeneration; ALS, amyotrophic lateral sclerosis.accuracy will ever be achieved for complex diseases, as
unraveling their complete causal pathways may be
impossible [32]. However, further genetic discoveries in
combination with other risk factors might eventually prove
the clinical utility of polygenic risk scores, as has been
shown for age-related macular degeneration and height
[33,34]. Importantly, the genetic variants that are currently
known explain only little of the variance in disease risk of
AD, PD, FTLD, and ALS. Uncovering the “missing
heritability” through larger GWAS and the novel focus on
rare variants could improve the clinical utility of genetic
risk scores. Additionally, the current genetic variants could
have a larger effect through gene-gene and gene-
environment interaction. The stratification for APOE ε4 car-
rier status showed differences in associations of the various
risk scores, but this needs to be explored further. Moreover,
nongenetic factors could aid in more accurately diagnosing
MCI and predicting dementia by themselves.
In conclusion, MCI is genetically heterogeneous,
whereas dementia develops through disease-specific mecha-
nisms. Future research should focus on disentangling
different genetic causes of MCI and the subsequent conver-
sion to dementia.mentia using models incorporating genetic risk scores for neurodegenerative
interval)
Area under the curve for conversion to dementia (95% confidence
interval)
tic
3/3458)
Total population
(n/N 5 191/3605)
Persons with MCI
(n/N 5 55/360)
Cognitively
normal persons
(n/N 5 136/3245)
3–0.644) 0.783 (0.751–0.815) 0.734 (0.666–0.802) 0.781 (0.744–0.818)
1–0.656) 0.801 (0.770–0.833) 0.744 (0.676–0.813) 0.803 (0.767–0.838)
5–0.665) 0.785 (0.752–0.817) 0.735 (0.667–0.803) 0.782 (0.745–0.819)
3–0.651) 0.782 (0.750–0.814) 0.734 (0.666–0.802) 0.780 (0.742–0.817)
1–0.653) 0.785 (0.753–0.817) 0.743 (0.678–0.808) 0.782 (0.745–0.819)
5–0.669) 0.791 (0.759–0.823) 0.733 (0.662–0.804) 0.792 (0.756–0.828)
E, apolipoprotein E; PD, Parkinson’s disease; FTLD, frontotemporal lobar
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1. Systematic review: We searched the literature for ge-
netic variants associated with neurodegenerative dis-
eases (Alzheimer’s disease [AD], Parkinson’s
disease [PD], frontotemporal lobar degeneration,
and amyotrophic lateral sclerosis) and mild cognitive
impairment (MCI) using PubMed and Google
Scholar. Although over 40 variants have been associ-
ated with neurodegenerative diseases, no genetic risk
factors of MCI are known besides the apolipoprotein
E (APOE) ε4 allele.
2. Interpretation: In a large prospective, population-
based cohort study, we investigated whether genetic
variants for neurodegenerative diseases also
contribute to MCI and the subsequent conversion to
dementia. All variants in aggregate were associated
with MCI, but only the AD variants also increased
risk of dementia, which was mainly of the Alz-
heimer’s type. This suggests that MCI is genetically
heterogeneous, whereas dementia develops through
disease-specific mechanisms.
3. Future directions: In addition to replication of these
findings for the genetic variants in aggregate,
exploring the effects of single variants could help pri-
oritize therapeutical targets by determining which
genes already influence cognition early in the disease
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